The promising selectivity and safety profile of Lugdunin and its derivatives suggest a high potential for development into a clinical drug product . Importantly, Lugdunin's structural characteristics fall within the chemical space of approved macrocyclic drugs, which bolsters the feasibility of advancing it toward clinical use . These advances render Lugdunin an exciting candidate in the ongoing battle against drug-resistant bacterial infections, with the potential to inspire the discovery of other "fibupeptides" based on similar scaffolds.